Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia B

Interventions

DRUG

activated recombinant human factor VII

Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)

Trial Locations (3)

Tel Litwinsky

Lille

München